How much cash does CorMedix generate?

CorMedix (CRMD) generated $197.7M in operating cash flow over the trailing twelve months.

What is CorMedix's free cash flow?

After $3.0M of capital expenditures, CorMedix's free cash flow was $194.7M over the trailing twelve months, up 1528.3% year over year.

Where does CorMedix's cash flow data come from?

Every line is extracted from CorMedix's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

CorMedix CRMD Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	$181.01M—	$163.06M—	——	——	——
Depreciation and amortization	$11.06M+3,659%	$677K+340%	$464.69K+411%	$328.24K+294%	$294.17K+289%
Stock-based compensation	$14.91M+108%	$13.83M+126%	$11.44M+85.9%	$8.6M+45.0%	$7.18M+25.6%
Deferred income taxes	——	——	——	——	——
Amortization of debt issuance costs	——	$398K—	——	——	——
Change in accounts receivable	$71.51M—	$90.92M—	$112.93M—	$42.84M—	——
Change in inventories	$4.61M-10.9%	$3.48M-36.7%	$3.63M-28.4%	$5.62M+90.1%	$5.17M+188%
Change in accounts payable	——	——	——	——	——
Change in accrued liabilities	$49.86M+94.1%	$100.77M+338%	$63.47M+546%	$18.11M+1,333%	$25.69M+1,655%
Change in other assets	——	——	——	——	——
Other working capital changes	——	——	——	——	-$46K—
Net cash from operating activities	$197.69M+1,557%	$175.05M+446%	$74.97M+234%	$30.46M+160%	-$13.57M+70.1%
Capital expenditures	$2.98M+4,505%	$2.26M+1,848%	$550.04K+36.9%	$54.03K-86.6%	$64.69K-82.7%
Purchases of investments	$30.79M+5.9%	$40.77M+52.3%	$44.82M+19.3%	$45.24M—	$29.06M—
Proceeds from maturities/sales of investments	$49.19M+19.3%	$55.29M+14.9%	$56.69M-5.7%	$30.9M-55.6%	$41.22M-37.8%
Net cash from investing activities	-$308.57M-2,589%	-$311.73M-1,548%	-$311.73M-1,548%	-$14.09M-196%	$12.39M+108%
Repurchases of common stock	——	——	——	——	——
Proceeds from issuance of common stock	——	——	——	——	——
Taxes paid for net share settlement	$2.5M+106%	$1.99M+586%	$1.78M+654%	$1.32M—	$1.21M—
Other financing activities	——	——	——	——	——
Payment of debt issuance costs	$323K—	$188K—	——	——	——
Net cash from financing activities	$221.68M+582%	$239.87M+811%	$251.15M+1,520%	$114.69M+159%	$32.51M-33.1%
Effect of exchange rate changes on cash	——	——	-$189—	——	——
Net increase (decrease) in cash	——	——	——	——	——
Interest paid	$2.82M+7,709%	$17K-52.8%	$26.28K-20.3%	$36.29K+0.6%	$36.17K+2.3%
Write-off of customer financing receivable	——	$18K—	——	——	——
Amortization expense related to capitalized debt issuance costs	——	$398K—	——	——	——
Contingent consideration fair value adjustments	——	$6.5M—	——	——	——
Change In Contingent Consideration	——	——	——	——	——
Gain (Loss), Foreign Currency Transaction, after Tax	——	-$100K—	-$75K-17,936%	-$50K-6,045%	-$25K-2,082%
Unrealized Gain (Loss), Foreign Currency Transaction, before Tax	——	$86K—	——	——	——
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	——	——
Other Noncash Income (Expense)	-$861K-479%	-$235K-71.5%	-$206.25K—	-$177.5K—	-$148.75K—
Payment Of Contingent Consideration Liabilities Operating Activities	——	——	——	——	——
Payments to Acquire Short-Term Investments	$37.97M+30.6%	$47.95M+79.1%	$53.17M+41.5%	$45.23M—	$29.06M—
Proceeds From Sale Of Short Term Investments	$49.19M+19.3%	$55.29M+14.9%	$56.69M-5.7%	$30.9M-55.6%	$41.22M-37.8%
Accrued payables for capital expenditures	——	——	——	——	——
Current Income Tax Expense (Benefit)	——	$12.76M+1,015%	$9.22M+1,474%	$5.68M+10,722%	$2.14M+176%
Discount Rate	——	——	——	——	——
Effective Income Tax Rate Reconciliation Deductions	——	——	——	——	——
Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent	——	——	——	——	——
Effective Income Tax Rate Reconciliation Transaction Cost	——	$2.12M—	——	——	——
Fair Value Adjustment Of Warrants	——	——	——	——	——
Leased assets obtained in exchange for operating lease liabilities	——	——	——	——	——
Issuances of common stock from employee benefit plans receivable	——	$49.29M—	——	——	——
Income Taxes Paid, Net	——	$62K+933%	$48K—	$34K—	$20K—
Free cash flow	$194.71M+1,528%	$172.79M+441%	$74.42M+233%	$30.41M+159%	-$13.63M+70.2%
Free cash flow	$194.71M+1,528%	$172.79M+441%	$74.42M+233%	$30.41M+159%	-$13.63M+70.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about CorMedix.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

How much cash does CorMedix generate?: CorMedix (CRMD) generated $197.7M in operating cash flow over the trailing twelve months.
What is CorMedix's free cash flow?: After $3.0M of capital expenditures, CorMedix's free cash flow was $194.7M over the trailing twelve months, up 1528.3% year over year.
Where does CorMedix's cash flow data come from?: Every line is extracted from CorMedix's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.